Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Specific HCC Antigens CD8+ T Cells in Relapsed/Advanced HCC
NCT03175705Phase 1Unknown
- Sponsor
- Beijing YouAn Hospital
- Start
- May 2017
- Primary completion
- Dec 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HCC antigens-specific CD8+ T lymphocytes in hepatocellular carcinoma (HCC), sponsored by Beijing YouAn Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 4 weeks. Status: unknown.
02
Drugs
HCC antigens-specific CD8+ T lymphocytes
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03175705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175705.